SCALE 1 post

• Not Apples to Apples: How Shifting Trial Criteria Distort GLP-1 Weight-Loss Headlines
  15 May 2026  ·  pharma LLY Novo Nordisk
  The headline weight-loss percentages from liraglutide, semaglutide, and tirzepatide trials look like a straight-line march of progress. They are not. Inclusion criteria have shifted systematically over a decade, changing who gets enrolled and for how long - making cross-trial comparisons unreliable without a head-to-head.